Physician profile
Gary D Goodnight
NPI 1487691432
$654.37
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $125 · 2021: $39.92 · 2022: $216 · 2023: $127 · 2024: $39.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $166.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $156.88 | 2019-2024 | Relieva Spinplus |
| Regeneron Healthcare Solutions, INC. | $110.04 | 2022-2023 | Dupixent |
| Glaxosmithkline, LLC. | $63.82 | 2022-2023 | Nucala |
| Stryker Corporation | $59.71 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.62 | 2022 | |
| Novartis Pharmaceuticals Corporation | $38.90 | 2019-2023 | |
| Smith+Nephew, INC. | $31.30 | 2020 | |
| Genentech USA, INC. | $30.59 | 2022-2023 | Xolair |
| Biocryst US Sales Co., LLC | $22.93 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.76 | 2021 | |
| Aerin Medical INC. | $19.16 | 2021 | |
| Csl Behring | $18.97 | 2022 | |
| Medtronic USA, INC. | $15.70 | 2020 | |
| Covidien LP | $12.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Goodnight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.